Targeted News Service

Roswell Park Launches Exclusive CD83 CAR T-Cell Clinical Trial for Patients with Relapsed or Refractory AML
April 14, 2026

BUFFALO, New York, April 14 [Category: BizHospital] -- The Roswell Park Comprehensive Cancer Center posted the following news release:

* * *

Roswell Park Launches Exclusive CD83 CAR T-Cell Clinical Trial for Patients with Relapsed or Refractory AML

*

Roswell Park Comprehensive Cancer Center has launched an exclusive phase 1 clinical trial of a new chimeric antigen receptor (CAR) T-cell therapy for patients whose acute myeloid leukemia (AML) has . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form